Confronting Dementia

First fully approved by the FDA in 2023, anti amyloid antibodies (lecanemab and donanemab) are the first class of medicines to definitively slow the progression of Alzheimer's Disease. Join me for a conversation with CPMC and Sutter Health's Dolby Center Medical Director Armen Moughamian MD, PhD to discuss what these exciting new treatments are, their potential benefits and risks, and which patients are good candidates for treatment. We also touch on some of the initial controversy surrounding these drugs and the clinical trials currently in progress using these medicines to potentially prevent Alzheimer's disease altogether! The episode is a great overview for anyone interested in learning more about the latest in Alzheimer's treatment.

This week we sit down for our first care partner episode with Rachel Main, Alzheimer's Association Family Support Coordinator, and experienced care partners Richard Mendelsohn, Kathleen Suryan, and Laurette Lau to share their initial experiences and reactions after receiving a diagnosis of Alzheimer's disease in their loved one. 

Welcome to the Confronting Dementia podcast! For our first episode, we sit down with Dr. Armen Moughamian MD, PhD Medical Director of Sutter Health’s Ray Dolby Brain Health Center to talk about the basics of dementia and Alzheimer's disease. We cover how dementia and Alzheimer's are different, how to get an evaluation, and the importance of early diagnosis. It's a great place to start for anyone interested in learning more about dementia basics. Join us!